ARWR — Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $194.3 million, or $1.36 per share, compared to a net loss of $175.2 million or $1.26 per share in Q3 2025.
• Revenue: Approximately $75 million, significantly up from $28 million in the prior year, driven by collaboration agreements and commercial sales of REDEMPLO.
• Collaboration Revenue: Included $26 million from Sarepta and $20 million from Novartis.
• Operating Expenses: Totaled approximately $245 million, up from $193 million in the prior year, primarily due to increased R&D and SG&A expenses.
• Cash Position: Approximately $1.6 billion as of June 30, 2026.

2. Strategic Updates and Business Highlights

• Clinical Trials: Positive Phase III results for plozasiran in severe hypertriglyceridemia (sHTG) were reported, with median triglyceride reductions of 79% and 81% in studies SHASTA-3 and SHASTA-4, respectively.
• Regulatory Strategy: Acquired a priority review voucher to expedite the FDA review process for plozasiran, potentially reducing the review time from 10 to 6 months.
• Commercial Launch: REDEMPLO's launch for familial chylomicronemia syndrome (FCS) has seen prescription volumes double quarter-over-quarter, with over 400 unique prescribers.
• International Expansion: REDEMPLO is now approved in multiple regions, including the U.S., Canada, Australia, and the EU, with ongoing reimbursement processes.

3. Forward Guidance and Outlook

• sNDA Submission: Planned submission for plozasiran by the end of 2026, contingent on pre-sNDA meeting with the FDA.
• Future Data Releases: Anticipated data readouts for ARO-DIMER-PA and ARO-MAPT in September, with additional data from other programs expected in Q4 2026.
• Market Strategy: Focus on high-risk sHTG patients initially, with plans to expand the sales force to address a broader market as education on triglyceride management increases.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The net loss increased year-over-year, raising concerns about the sustainability of current spending levels.
• Operating Expenses: Significant rise in R&D and SG&A expenses may impact future profitability if revenue does not scale accordingly.
• Market Education: The company acknowledges that educating healthcare providers and patients about triglyceride management will take time, potentially slowing initial market uptake for sHTG.
• Competitive Landscape: The launch of competing products may pose challenges, and Arrowhead's pricing strategy will need to justify its premium over competitors.

5. Notable Q&A Insights

• sNDA Timeline: Management indicated that the timeline for the sNDA submission depends on the completion of necessary modules and discussions with the FDA.
• ESC Data Presentation: Details on the SHASTA studies will be presented at the European Society of Cardiology meeting, with management under embargo until then.
• Sales Force Expansion: The sales force is expected to grow significantly, from targeting 5,000 healthcare providers to over 20,000 as they prepare for the sHTG launch.
• Pricing Strategy: Management confirmed that they do not plan to adjust the price of REDEMPLO despite competitive pressures, citing its differentiated profile as justification for the current pricing.

This summary encapsulates Arrowhead Pharmaceuticals' Q3 2026 earnings call, highlighting financial performance, strategic initiatives, and future outlook while addressing potential challenges and insights from the Q&A session.